Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, entered into a securities purchase agreement with certain existing accredited investors to issue and sell shares of its common stock. Denali anticipates the gross proceeds to be approximately $500 million.    Proceeds from the financing are expected to be used to...